Nazli Dizman, MD, an Internal Medicine Resident at Yale University, spoke with us about the recent study that she contributed to on the combination of pembrolizumab and axitinib as a second- and further-line treatment for metastatic renal cell carcinoma. She describes the factors that may contribute to a positive outcome in patients when receiving this combination, along with it’s potential to become a standard of care further-line treatment in the future.
View Dr. Dizman’s other comments on the future of further-line mRCC treatments.